Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Health Care

57.68
+1.252.21%
Volume:12.30K
Turnover:714.17K
Market Cap:96.33M
PE:- -
High:58.27
Open:58.16
Low:57.61
Close:56.43
52wk High:64.60
52wk Low:39.32
Shares:1.67M
Float Shares:1.67M
Volume Ratio:6.02
T/O Rate:0.74%
Dividend:0.71
Dividend Rate:1.22%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
Sep 04

Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results

TIPRANKS
·
Sep 04

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Dow Jones
·
Sep 04

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Sep 03

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Sep 03

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Sep 03

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Sep 03

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS
·
Sep 03

Abbvie Announces Positive Topline Results from the Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 03

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

MT Newswires Live
·
Sep 03

Apogee Therapeutics Shares Face NASDAQ Suspension as Company Moves to Delist After AbbVie Merger

Reuters
·
Sep 03

Aspen Sees Mounjaro Africa Sales Above $124 Million in 2027

Reuters
·
Sep 03

Abbvie Completes Acquisition of Apogee Therapeutics

THOMSON REUTERS
·
Sep 03

Abbvie - Reaffirms 2026 Q3 Adj Diluted EPS Guidance $3.84-$3.88

THOMSON REUTERS
·
Sep 03

AbbVie to Present at Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 03

Superluminal Medicines: Financing Led by Bvf Partners; Alongside Existing Investors Nvidia, Eli Lilly & Co, Cooley, and Gaingels, Among Others

THOMSON REUTERS
·
Sep 03

Rothschild & Co Redburn Adjusts PT on Eli Lilly and Co. to $930 From $915, Keeps Neutral Rating

MT Newswires Live
·
Sep 03